Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clinical investigation for the treatment of HCV infection. The poor fidelity of the HC...

Deskribapen osoa

Xehetasun bibliografikoak

Argitaratua izan da:	Antimicrob Agents Chemother
Egile Nagusiak:	Lu, Liangjun, Pilot-Matias, Tami J., Stewart, Kent D., Randolph, John T., Pithawalla, Ron, He, Wenping, Huang, Peggy P., Klein, Larry L., Mo, Hongmei, Molla, Akhteruzzaman
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	American Society for Microbiology (ASM) 2004
Gaiak:	Antiviral Agents
Sarrera elektronikoa:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC415624/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15155230/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.6.2260-2266.2004
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!